Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta

Neurological Sciences

Volumn 28, Issue 3, 2007, Pages 121-126

  Saraste, M ^a   Irjala, H ^a,b   Airas, Laura ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Interferon beta; Multiple sclerosis; NK cell

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CD56 ANTIGEN; INTERFERON BETA SERINE; BIOLOGICAL RESPONSE MODIFIER;

ADULT; ARTICLE; CELL INTERACTION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CONTROL; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOID TISSUE; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; BLOOD; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; MIDDLE AGED;

ADULT; ANTIGENS, CD56; BIOLOGICAL RESPONSE MODIFIERS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTERFERON-BETA; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 34447290007     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-007-0803-3     Document Type: Article

References (26)

1. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199:971-979
2. Takahashi K, Aranami T, Endoh M et al (2004) The regulatory role of natural killer cells in multiple sclerosis. Brain 127:1917-1927
3. Takahashi K, Miyake S, Kondo T et al (2001) Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest 107:R23-R29
4. Infante-Duarte C, Weber A, Kratzschmar J et al (2005) Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J 19:1902-1904
5. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
6. Yong VW (2002) Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 59:802-808
7. Perini P, Wadhwa M, Buttarello M et al (2000) Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients. J Neuroimmunol 105:91-95
8. Kastrukoff LF, Morgan NG, Zecchini D et al (1998) A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol 86:123-133
9. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633-640
10. Li Z, Lim WK, Mahesh SP et al (2005) Cutting edge: In vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 174:5187-5191
11. Cooper MA, Fehniger TA, Turner SC et al (2001) Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 97:3146-3151
12. Campbell JJ, Qin S, Unutmaz D et al (2001) Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 166:6477-6482
13. Fehniger TA, Cooper MA, Nuovo GJ et al (2003) CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: A potential new link between adaptive and innate immunity. Blood 101:3052-3057
14. Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25:297-336
15. Dalbeth N, Callan MF (2002) A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum 46:1763-1772
16. Bielekova B, Catalfamo M, Reichert-Scrivner S et al (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103:5941-5946
17. Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG (2002) The natural killer cell - friend or foe in autoimmune disease? Scand J Immunol 55:432-441
18. Morse RH, Seguin R, McCrea EL, Antel JP (2001) NK cell-mediated lysis of autologous human oligodendrocytes. J Neuroimmunol 116:107-115
19. Shi FD, Takeda K, Akira S et al (2000) IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol 165:3099-3104
20. Traugott U, Raine CS (1984) Further lymphocyte characterization in the central nervous system in multiple sclerosis. Ann N Y Acad Sci 436:163-180
21. Matsumoto Y, Kohyama K, Aikawa Y et al (1998) Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. Eur J Immunol 28:1681-1688
22. Weber WE, Buurman WA, Vandermeeren MM et al (1987) Fine analysis of cytolytic and natural killer T lymphocytes in M. the CSF in multiple sclerosis and other neurologic diseases. Neurology 37:419-425
23. Zhang B, Yamamura T, Kondo T et al (1997) Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 186:1677-1687
24. Smeltz RB, Wolf NA, Swanborg RH (1999) Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. J Immunol 163:1390-1397
25. Xu W, Fazekas G, Hara H, Tabira T (2005) Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J Neuroimmunol 163:24-30
26. Huang D, Shi FD, Jung S et al (2006) The neuronal chemokine CX3CL1/ fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 20:896-905